Melanoma & Skin Cancer | Specialty

The OncLive Melanoma & Skin Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of skin cancers, including melanoma, basal cell carcinoma, and more. This section features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in melanoma and other skin cancers.

Spartalizumab/Dabrafenib Misses PFS End Point in Melanoma

September 19th 2020

Spartalizumab plus dabrafenib did not significantly improve progression-free survival over dabrafenib/trametinib in patients with untreated BRAF V600-mutant unresectable or metastatic melanoma.

Higher PFS Rate Reported for Encorafenib/Binimetinib Combo Followed by Immunotherapy in Metastatic Melanoma

September 19th 2020

Early findings from a phase II efficacy and safety study may be the first step in developing a definitive rationale for sequencing targeted therapies and immunotherapies in patients with metastatic melanoma.

Cemiplimab Shows Clinical Benefit in Locally Advanced Basal Cell Carcinoma Following Hedgehog Inhibition

September 18th 2020

The PD-1 antibody cemiplimab established encouraging clinical activity in patients with locally advanced basal cell carcinoma who progress on or are intolerant to hedgehog inhibitors, regardless of PD-L1 expression.

Dr. Stratigos the Rationale to Evaluate Cemiplimab in Locally Advanced BCC

September 18th 2020

Alexander J. Stratigos, MD, discusses the rationale to evaluate cemiplimab-rwlc in locally advanced basal cell carcinoma.

FDA Approval Insights: Atezolizumab Plus Cobimetinib and Vemurafenib in BRAF V600+ Advanced Melanoma

September 17th 2020

In our exclusive interview, Omid Hamid, MD, contextualizes the FDA approval of atezolizumab in combination with cobimetinib and vemurafenib in BRAF V600 mutation–positive advanced melanoma and discusses important takeaways from the IMspire150 trial.

Dr. Shoushtari on the Role of Nivolumab and Ipilimumab in Mucosal Melanoma

September 16th 2020

Alexander N. Shoushtari, MD, discusses the role of nivolumab and ipilimumab in mucosal melanoma.

Dr. Johnson on the Need for Novel Biomarkers in Melanoma

September 15th 2020

Douglas B. Johnson, MD, MSCI, discusses the need to identify novel biomarkers in melanoma.

Hamid Highlights Emerging Biomarkers for Immunotherapy in Melanoma

September 10th 2020

Omid Hamid, MD, discusses emerging biomarkers in melanoma, data supporting their efficacy and their potential for use in clinical practice, and future directions for research.

Novel Nomogram Effectively Estimates Risk of Sentinel Node Metastases in Melanoma

September 4th 2020

The Melanoma Institute Australia nomogram was found to accurately estimate the risk of sentinel node metastasis positivity in patients with melanoma and its use could help to reduce the rate of unnecessary invasive biopsies without sacrificing sensitivity.

Dr. Blank on the OpACIN, OpACIN-neo Trials in Stage III Macroscopic Melanoma

September 3rd 2020

Christian U. Blank, MD, PhD, discusses the OpACIN and OPACIN-neo trials examining ipilimumab plus nivolumab in stage III macroscopic melanoma.

The Dilemma of New Evidence: When to Shift Gears

August 29th 2020

When is it appropriate to accept a specific strategy, either formally or informally, as a standard-of-care option in managing the treatment of patients with cancer in a particular clinical setting?

Dr. Long on the Rationale for the Phase 3 COMBI-i Trial in BRAF V600¬–Mutant Melanoma

August 28th 2020

Georgina Long, BSc, PhD, MBBS, FRACP, discusses the rationale for the phase 3 COMBI-i trial in BRAF V600–mutant melanoma.

Garutti Examines Advantages of Neoadjuvant Approaches in Melanoma

August 28th 2020

Mattia Garutti, MD, discusses the advantages of neoadjuvant therapy, predictive biomarkers under exploration, and future neoadjuvant clinical trial development.

Dr. Hamid on TMB as a Biomarker for Immunotherapy Response in Melanoma

August 24th 2020

Omid Hamid, MD, discusses the utility of tumor mutational burden as a biomarker for response to immunotherapy in patients with melanoma.

Spartalizumab Plus Dabrafenib/Trametinib Misses PFS End Point in BRAF V600+ Melanoma

August 24th 2020

Spartalizumab in combination with dabrafenib and trametinib failed to meet the primary end point of investigator-assessed progression-free survival in treatment-naïve patients with unresectable or metastatic BRAF V600 mutation–positive cutaneous melanoma.

Dr. Johnson on the Limitations of Biomarkers in Melanoma

August 20th 2020

Douglas B. Johnson, MD, MSCI, discusses the limitations of biomarkers in melanoma.

Dr. Pavlick on Longer Follow-Up Data With Cemiplimab in CSCC

August 19th 2020

Anna C. Pavlick, DO, discusses the longer follow-up of the phase 2 EMPOWER-CSCC-1 study with cemiplimab in cutaneous squamous cell carcinoma.

Dr. Atlas on the Promise of Up-Front Cemiplimab in Locally Advanced CSCC

August 19th 2020

Jennifer L. Atlas, MD, discusses the promise of cemiplimab in the treatment of patients with locally advanced cutaneous squamous cell carcinoma.

Experts Examine Emerging Approaches in Melanoma Management

August 18th 2020

A panel of experts discuss some of the encouraging data on emerging modalities in melanoma presented during the 2020 ASCO Virtual Scientific Program and share how they might apply that information to clinical practice.

Dr. Weber on Emerging Therapies in Melanoma

August 17th 2020

Jeffrey S. Weber, MD, PhD, discusses emerging therapies in melanoma.